Lingjun N. Zhu

300 GuangZhou Rd
Nanjing, 210029, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 74 publications

APOE+ macrophages induce tumor cell metastatic characteristics via TNFSF12/TNFRSF12A signaling, correlating with poor patient prognosis.

APOE+ macrophages induce tumor cell metastatic characteristics via TNFSF12/TNFRSF12A signaling, correlating with poor patient prognosis.

Journal: Cancer cell international

Published: July 14, 2025

APOL6 as a potential biomarker of immuno-correlation and therapeutic prediction in cancer immunotherapy.

APOL6 as a potential biomarker of immuno-correlation and therapeutic prediction in cancer immunotherapy.

Journal: Medicine

Published: May 12, 2025

COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition.

COL1A1-positive endothelial cells promote gastric cancer progression via the ANGPTL4-SDC4 axis driven by endothelial-to-mesenchymal transition.

Journal: Cancer letters

Published: October 31, 2024

Peripheral blood lymphocyte subpopulations as predictive biomarkers for first-line programmed death 1 inhibitors efficacy in esophageal squamous cell carcinoma: A retrospective study.

Peripheral blood lymphocyte subpopulations as predictive biomarkers for first-line programmed death 1 inhibitors efficacy in esophageal squamous cell carcinoma: A retrospective study.

Journal: Medicine

Published: October 28, 2024

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.

Journal: Signal transduction and targeted therapy

Published: July 31, 2024

KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer.

KMT2A Mutations and High Prevalence of dMMR-associated Mutational Signatures as Prognostic Indicators in Metastatic Colorectal Cancer.

Journal: Journal of Cancer

Published: January 18, 2024

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.

Journal: EBioMedicine

Published: August 18, 2023

Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.

Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.

Journal: BMC cancer

Published: June 30, 2023

Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers.

Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers.

Journal: Frontiers in oncology

Published: January 30, 2023

Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer.

Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer.

Journal: Cell reports. Medicine

Published: August 28, 2022

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 22, 2022

METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner.

METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner.

Journal: Biochemical and biophysical research communications

Published: April 14, 2022

Showing 1-12 of 74

Last Updated: 09/26/2026